Ranjeny Thomas
University of Queensland, QLD, Australia
- This delegate is presenting an abstract at this event.
Professor Thomas is Professor of Rheumatology at University of Queensland, Translational Research Institute, consultant rheumatologist at Princess Alexandra Hospital, fellow of the Australian Academy of Health and Medical Sciences and member of the Order of Australia. She has founded two spin-off companies Dendright (2006-2021), and Liperate in 2022. Liperate recently opened a trial of a liposome-based tolerance immunotherapy for type 1 diabetes. Ranjeny and her team were recently awarded a MRFF Frontiers grant towards the moonshot goal of a cure for rheumatoid arthritis.
Presentations this author is a contributor to:
Gene expression in peripheral blood of pre-diabetic NOD mice predicts onset of type 1 diabetes and identifies new clinical biomarkers (#172)
6:00 PM
Dimeng Pang
POSTER SESSION 2 / DRINKS
Analysis of immune, metabolic and clinical biomarkers implicates inflammatory and stress pathways in the pre-clinical development of type 1 diabetes (#155)
6:00 PM
Mark Harris
POSTER SESSION 2 / DRINKS
Analysis of immune, metabolic and clinical biomarkers implicates inflammatory and stress pathways in the pre-clinical development of type 1 diabetes (#44)
11:15 AM
Ranjeny Thomas
ANTIGENS AND BIOMARKERS II
IL-10 receptor and endoplasmic reticulum stress impairs STAT3 activation in type 1 diabetes patients and their healthy first degree relatives (#117)
5:05 PM
Mamdouh Sedhom
POSTER SESSION 1 / DRINKS
IDS 2013*